Equity Overview
Price & Market Data
Price: $1.54
Daily Change: +$0.05 / 3.25%
Range: $1.54 - $1.54
Market Cap: $9,411,689
Volume: 295
Performance Metrics
1 Week: 10.37%
1 Month: -19.46%
3 Months: -37.39%
6 Months: -88.71%
1 Year: -93.09%
YTD: -64.75%
Company Details
Employees: 46
Sector: Health technology
Industry: Biotechnology
Country: Denmark
Details
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.